Skip to content

Effects of Vitamin D Supplementation on Strength, Bone Density, and Injury Risk in Collegiate Athletes

Vitamin D, Strength, and Bone Density in Collegiate Athletes

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03151174
Enrollment
68
Registered
2017-05-12
Start date
2017-04-29
Completion date
2018-06-01
Last updated
2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitamin D Deficiency

Brief summary

The goal of this study is to determine whether Vitamin D supplementation improves strength and bone density, and reduces the risk of injury in collegiate athletes.

Detailed description

Vitamin D is a hormone that is important for bone and muscle health. As such, not having enough vitamin D in your body is associated with increased risk of injury and reduced health and athletic performance. It is often recommended that individuals who have low levels of vitamin D take vitamin D supplements. However, the effects of vitamin D supplementation on health and strength gains in collegiate athletes are not known. The goal of this study is to determine whether vitamin D supplementation increases strength and bone density, while reducing the risk of injury in collegiate athletes. Fasting vitamin D concentrations will be measured and athletes will be supplemented daily with Vitamin D for 8-12 weeks. The amount of supplementation will depend on whether the athlete is categorized as sufficient (\>30ng/ml), insufficient (20-35ng/ml), or deficient (\<20ng/ml). Vitamin D concentrations, strength, bone density, and injury risk will be assessed before and after the intervention period.

Interventions

DRUGVitamin D 5000 UNT

5000 IU Vitamin D per day

DRUGVitamin D 10000 UNT

10000 IU Vitamin D per day

Sponsors

Virginia Polytechnic Institute and State University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

Any individuals involved in study measures will also be masked.

Intervention model description

Subjects will either receive placebo, 5000IU, or 10000IU per day of Vitamin D for 8-12 weeks.

Eligibility

Sex/Gender
ALL
Age
18 Years to 30 Years
Healthy volunteers
Yes

Inclusion criteria

* athlete for a sanctioned Virginia Tech sport

Exclusion criteria

* pregnant or trying to become pregnant, currently taking vitamin D (\>600IU/day), calcium (\>1000mg/dl), taking any performance enhancing supplements (example, creatine), or any other medication or nutritional supplements that might influence the study variables, cardiac or thyroid problems, have diabetes, or epilepsy

Design outcomes

Primary

MeasureTime frameDescription
StrengthUp to 12 weeksOverall strength assessed via maximal strength testing. The specific tests may include the following, 1) one repetition max bench press (lbs) -, 2) one repetition max squat (lbs), 3) vertical jump test (feet), 4) broad jump test (feet), 5) dead lifts (lbs and repetition), 6) pull ups (repetition), 7) dips (repetition), and 8) shuttle time (test involving repeated sprints to and from marked points or lines - minutes/ seconds).

Secondary

MeasureTime frameDescription
Femur Bone DensityUp to 12 weeksBone Density will be assessed in spine using Dual Energy X-ray Absorptiometry. T-scores will be determined.
Spine Bone DensityUp to 12 weeksBone Density will be assessed in the hip (proximal femur) using Dual Energy X-ray Absorptiometry. T-scores will be determined.
Injury OccurenceEvery week for up to 12 weeksNew and current Injuries including bone breaks, muscle strains and sprains will be tracked via a questionnaire that will be filled out weekly. Subjects will report whether they had an injury, where the injury occurred on the body, the type of injury, as well as the date/ time of the injury and how the injury occurred. Number of injury

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026